Pharmacy and Poisons Board

Pharmacy and Poisons Board

Ensuring Safety, Quality and Efficacy of Medicines

Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 38, showing 5 Applications out of 186 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Application Status

26.

ECCT/16/11/04   RV456
    A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo   
Principal Investigator(s)
1. JANET OYIEKO
Site(s) in Kenya
KOMBEWA CLINICAL RESEARCH CENTRE
 
Trial Status In follow-up
Protocol Date 08-03-2016
View

27.

ECCT/16/11/05   RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
    A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo.   
Principal Investigator(s)
1. Fredrick Kipyego Sawe
Site(s) in Kenya
1. KEMRI/WRP Kericho (Kericho county)
2. KEMRI/WRP Kombewa, Kisumu (Kisumu county)
 
Trial Status recruiting
Protocol Date 08-03-2016
View

28.

ECCT/16/11/03   COAST
    Childrens Oxygen Administration Strategies Trial   
Principal Investigator(s)
1. Kathryn Maitland
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast Provincial General Hospital (Mombasa county)
 
Trial Status recruiting
Protocol Date 15-09-2016
View

29.

ECCT/16/09/03   Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya.
    Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya.   
Principal Investigator(s)
1. Dr.Pauline NM Mwinzi
Site(s) in Kenya
KEMRI CGHR
 
Trial Status recruiting
Protocol Date 25-05-2016
View

30.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
Trial Status (not set!)
Protocol Date 13-04-2016
View